50 results on '"Smith, David C."'
Search Results
2. Papermaking in America by Norman B. Wilkinson (review)
3. Bowater: A History by W. J. Reader (review)
4. Leveraged finance
5. Initial impacts of the COVID-19 pandemic on Australian fisheries production, research organisations and assessment: shocks, responses and implications for decision support and resilience
6. First-in-Human Study of INCB062079, a Fibroblast Growth Factor Receptor 4 Inhibitor, in Patients with Advanced Solid Tumors
7. INTRODUCTION: LAWRENCE CANE’S FIGHT AGAINST FASCISM
8. Île Dumet (Armorican Massif, France) and its glaucophane eclogites: the little sister of Île de Groix
9. The contribution of water radiolysis to marine sedimentary life
10. Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas
11. Supplementary Table S1 from Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers
12. Supplementary Figure S1 from Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers
13. Data from Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers
14. Data from Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature
15. Supplementary Methods from Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers
16. Supplementary Figures S1 - S6, Tables S1 - S2 from Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature
17. Carbon Capture And Sequestration-'Essential,' But Too Little, Too Late?
18. The Supreme Court Provides Clarity And Contraction On Regulation Of Waters Of The United States
19. Berkeley's Natural Gas Ban In New Housing And Businesses Not Allowed, Says Ninth Circuit
20. Supplementary Figure 1 from Characterization of Bone Metastases from Rapid Autopsies of Prostate Cancer Patients
21. Supplementary Table 1 from Characterization of Bone Metastases from Rapid Autopsies of Prostate Cancer Patients
22. Supplementary Figure 2 from Characterization of Bone Metastases from Rapid Autopsies of Prostate Cancer Patients
23. Supplementary Data from Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies
24. Supplementary Figure and Table Legends from Characterization of Bone Metastases from Rapid Autopsies of Prostate Cancer Patients
25. Supplemental Tables 1-4 from A Phase I Dose Escalation and Expansion Study of the Anticancer Stem Cell Agent Demcizumab (Anti-DLL4) in Patients with Previously Treated Solid Tumors
26. Supplementary Table 2 from Characterization of Bone Metastases from Rapid Autopsies of Prostate Cancer Patients
27. OSU 541.147 Hazelnut
28. Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
29. A Phase 2 Trial of Nab-paclitaxel in Combination With Anti-PD1 Therapy in Advanced Urothelial Cancer
30. Mandatory Climate Emissions Disclosures: California Lawmakers Press On While SEC May Be Backing Off
31. Archie Hutchison
32. Prostate Cancer With Peritoneal Carcinomatosis: A Robotic-assisted Radical Prostatectomy-based Case Series
33. Incidental testicular germ cell tumor in a transgender woman: A case report
34. Outpatient administration of paclitaxel, ifosfamide, and cisplatin (TIP) for germ cell tumor.
35. Focal radiation with pulsed systemic therapy of abiraterone, androgen deprivation therapy (ADT), olaparib towards castration-sensitive oligometastatic prostate cancer (FAALCON Trial).
36. Brucella suis and farm biosecurity: assessing risk in pigs raised outdoors in New York State
37. Analysis Of SEC's And California Legislature's Proposed Corporate Greenhouse Gas Reporting Mandates
38. ABLE: Phase 2, single-arm, two-stage study of nabpaclitaxel with anti-PD1/PDL1 in advanced urothelial cancer.
39. Targeting resistant prostate cancer, with or without DNA repair defects, using the combination of ceralasertib (ATR inhibitor) and olaparib (the TRAP trial).
40. Confining the growth of mesoporous silica films into nanospaces: towards surface nanopatterning
41. CEQA To Project Proponents: 'Why Can't You Do Solar?'
42. Just As EPA Was Fixing Wetlands Rules, Along Come The Sacketts . . . Again
43. Multigene Profiling of Circulating Tumor Cells (CTCs) for Prognostic Assessment in Treatment-Naïve Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
44. Electrodeposition of GeSbTe-Based Resistive Switching Memory in Crossbar Arrays
45. Insights into hyperbolic phonon polaritons in h−BN using Raman scattering from encapsulated transition metal dichalcogenide layers
46. The Effects of Hydrogen Annealing on Carbon Nanotube Field-Effect Transistors
47. Private Equity and the Resolution of Financial Distress
48. LETTERS TO THE EDITOR.
49. Multigene Profiling of Circulating Tumor Cells (CTCs) for Prognostic Assessment in Treatment-Naïve Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).
50. A Phase 2 Trial of Nab-paclitaxel in Combination With Anti-PD1 Therapy in Advanced Urothelial Cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.